Literature DB >> 2140997

Severe hepatitis caused by cyproterone acetate.

J C Blake1, A M Sawyerr, J S Dooley, P J Scheuer, N McIntyre.   

Abstract

A case of severe acute hepatitis caused by cyproterone acetate in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug. The association between the use of cyproterone acetate and liver abnormalities is poorly documented. This is the fourth published report of adverse hepatic reaction to cyproterone acetate and it substantiates other evidence that cyproterone acetate is potentially hepatotoxic. Monitoring of liver function tests should be mandatory in patients receiving high doses of cyproterone acetate; the drug should be withdrawn immediately if abnormal liver function tests are found.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140997      PMCID: PMC1378574          DOI: 10.1136/gut.31.5.556

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  4 in total

1.  Fulminant hepatitis due to cyproterone acetate.

Authors:  H Lévesque; C Trivalle; N D Manchon; J P Vinel; N Moore; J Hémet; H Courtois; E Bercoff; J Bourreille
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

2.  Hepatocellular damage by cyproterone acetate.

Authors:  W H Meijers; P H Willemse; D T Sleijfer; N H Mulder; J Grond
Journal:  Eur J Cancer Clin Oncol       Date:  1986-09

Review 3.  Pharmacology and potential use of cyproterone acetate.

Authors:  F Neumann
Journal:  Horm Metab Res       Date:  1977-01       Impact factor: 2.936

4.  Liver structure and function during long-term treatment with cyproterone acetate.

Authors:  E Kaiser; H S Gruner
Journal:  Arch Gynecol       Date:  1987
  4 in total
  5 in total

Review 1.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Antiandrogens in prostate cancer.

Authors:  P Reid; P Kantoff; W Oh
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 3.  Fatal fulminant hepatic failure due to cyproterone acetate.

Authors:  G Friedman; E Lamoureux; A H Sherker
Journal:  Dig Dis Sci       Date:  1999-07       Impact factor: 3.199

Review 4.  Hepatotoxicity induced by cyproterone acetate: a report of three cases.

Authors:  Ioanna Savidou; Melanie Deutsch; Aspasia S Soultati; Dimitrios Koudouras; Georgia Kafiri; Spyridon P Dourakis
Journal:  World J Gastroenterol       Date:  2006-12-14       Impact factor: 5.742

Review 5.  Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.

Authors:  L B Barradell; D Faulds
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.